德展健康：参股公司东方略在研重点产品VGX-3100截至目前尚未完成三期临床试验

Group 1 - The core issue raised by investors is the lack of announcement regarding the completion of the Phase III clinical trial for the VGX-3100 vaccine developed by Beijing Oriental Lue [1] - The company, Dezhan Health, stated that the Phase III clinical trial for VGX-3100, which targets HPV-16 and/or HPV-18 related high-grade cervical precancerous lesions, has completed patient enrollment [1] - As of now, the Phase III clinical trial has not been fully completed, and the company will fulfill its information disclosure obligations as required by regulations if there are any relevant matters concerning Oriental Lue [1]